this post was submitted on 31 May 2024
225 points (99.1% liked)

World News

39032 readers
2267 users here now

A community for discussing events around the World

Rules:

Similarly, if you see posts along these lines, do not engage. Report them, block them, and live a happier life than they do. We see too many slapfights that boil down to "Mom! He's bugging me!" and "I'm not touching you!" Going forward, slapfights will result in removed comments and temp bans to cool off.

We ask that the users report any comment or post that violate the rules, to use critical thinking when reading, posting or commenting. Users that post off-topic spam, advocate violence, have multiple comments or posts removed, weaponize reports or violate the code of conduct will be banned.

All posts and comments will be reviewed on a case-by-case basis. This means that some content that violates the rules may be allowed, while other content that does not violate the rules may be removed. The moderators retain the right to remove any content and ban users.


Lemmy World Partners

News !news@lemmy.world

Politics !politics@lemmy.world

World Politics !globalpolitics@lemmy.world


Recommendations

For Firefox users, there is media bias / propaganda / fact check plugin.

https://addons.mozilla.org/en-US/firefox/addon/media-bias-fact-check/

founded 1 year ago
MODERATORS
 

Doctors are hailing “off the chart” trial results that show a new drug stopped lung cancer advancing for longer than any other treatment in medical history.

Lung cancer is the world’s leading cause of cancer death, accounting for about 1.8m deaths every year. Survival rates in those with advanced forms of the disease, where tumours have spread, are particularly poor.

More than half of patients (60%) diagnosed with advanced forms of lung cancer who took lorlatinib were still alive five years later with no progression in their disease, data presented at the world’s largest cancer conference showed. The rate was 8% in patients treated with a standard drug, the trial found.

The results are the longest progression-free survival (PFS) outcomes ever recorded in patients with non-small cell lung cancer, the world’s most common form of the disease. They were presented at the annual meeting of the American Society of Clinical Oncology (Asco) in Chicago on Friday.

you are viewing a single comment's thread
view the rest of the comments
[–] autotldr@lemmings.world 4 points 5 months ago

This is the best summary I could come up with:


Doctors are hailing “off the chart” trial results that show a new drug stopped lung cancer advancing for longer than any other treatment in medical history.

The results are the longest progression-free survival (PFS) outcomes ever recorded in patients with non-small cell lung cancer, the world’s most common form of the disease.

“To our knowledge these results are unprecedented,” said the study’s lead author, Dr Benjamin Solomon, a medical oncologist at the Peter MacCallum Cancer Centre in Melbourne, Australia.

“You don’t need a magnifying glass to see the difference between these two drugs,” said Dr Julie Gralow, Asco’s chief medical officer.

Dr David Spigel, the chief scientific officer of the Sarah Cannon Research Institute in London, a world-leading clinical trials facility specialising in new therapies for cancer patients, welcomed the findings.

“Showcasing the power of cancer-growth blocker drugs, this study could present us with an effective way of stopping cancer in its tracks and preventing it from spreading to the brain.


The original article contains 639 words, the summary contains 161 words. Saved 75%. I'm a bot and I'm open source!